Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Artiva Biotherapeutics, Inc.
Recent SEC filings with analysis
- 8-KArtiva Biotherapeutics is halting all further development of AlloNK (AB-101), its lead allogeneic NK cell therapy, including the planned Phase 3 pivotal trial…
- 8-KArtiva Biotherapeutics stockholders approved an amendment to the 2024 Equity Incentive Plan at the September 8, 2026 annual meeting, increasing shares…